# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001213900-24-076184
Filing Date
2024-09-05
Accepted
2024-09-05 17:18:25
Documents
36
Period of Report
2024-08-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.02: Results of Operations and Financial Condition
Item 3.03: Material Modifications to Rights of Security Holders
Item 4.01: Changes in Registrant's Certifying Accountant
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 5.06: Change in Shell Company Status
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | CURRENT REPORT | ea0213193-8k_orukathera.htm iXBRL | 8-K | 297575
2 | CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF | ea021319301ex3-1_oruka.htm | EX-3.1 | 7601
3 | CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF | ea021319301ex3-2_oruka.htm | EX-3.2 | 7602
4 | CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF | ea021319301ex3-3_oruka.htm | EX-3.3 | 6489
5 | CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF | ea021319301ex3-4_oruka.htm | EX-3.4 | 8875
6 | AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, FILED SEPTEMBE | ea021319301ex3-5_oruka.htm | EX-3.5 | 26746
7 | AMENDED AND RESTATED BYLAWS OF THE COMPANY | ea021319301ex3-6_oruka.htm | EX-3.6 | 152087
8 | FORM OF CERTIFICATE OF ELIMINATION OF CERTIFICATE OF DESIGNATION OF PREFERENCES, | ea021319301ex3-8_oruka.htm | EX-3.8 | 9386
9 | FORM OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SER | ea021319301ex3-9_oruka.htm | EX-3.9 | 71073
10 | ORUKA THERAPEUTICS, INC. 2024 STOCK INCENTIVE PLAN | ea021319301ex10-10_oruka.htm | EX-10.10 | 113469
11 | ORUKA THERAPEUTICS, INC. 2024 EMPLOYEE STOCK PURCHASE PLAN | ea021319301ex10-11_oruka.htm | EX-10.11 | 82081
12 | SECOND AMENDMENT TO AMENDED AND RESTATED ORUKA THERAPEUTICS, INC. 2024 EQUITY IN | ea021319301ex10-13_oruka.htm | EX-10.13 | 11652
13 | FORM OF EMPLOYEE WARRANT AGREEMENT | ea021319301ex10-16_oruka.htm | EX-10.16 | 34388
14 | CONSULTING AGREEMENT, EFFECTIVE AS OF AUGUST 30, 2024, BY AND BETWEEN ORUKA THER | ea021319301ex10-25_oruka.htm | EX-10.25 | 76344
15 | CODE OF BUSINESS CONDUCT AND ETHICS OF ORUKA THERAPEUTICS, INC | ea021319301ex14-1_oruka.htm | EX-14.1 | 86667
16 | LETTER FROM KPMG LLP, DATED SEPTEMBER 5, 2024 | ea021319301ex16-1_oruka.htm | EX-16.1 | 2741
17 | LIST OF SUBSIDIARIES OF ORUKA THERAPEUTICS, INC | ea021319301ex21-1_oruka.htm | EX-21.1 | 2260
18 | PRESS RELEASE, ISSUED ON SEPTEMBER 3, 2024 | ea021319301ex99-1_oruka.htm | EX-99.1 | 12993
19 | AUDITED FINANCIAL STATEMENT OF ORUKA THERAPEUTICS, INC. AS OF FEBRUARY 6, 2024 | ea021319301ex99-2_oruka.htm | EX-99.2 | 52736
20 | UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF ORUKA THERAPEUT | ea021319301ex99-3_oruka.htm | EX-99.3 | 231546
21 | MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERA | ea021319301ex99-4_oruka.htm | EX-99.4 | 150801
22 | UNAUDITED PRO FORMA FINANCIAL STATEMENTS OF ORUKA THERAPEUTICS, INC. AND ARCA BI | ea021319301ex99-5_oruka.htm | EX-99.5 | 244728
23 | GRAPHIC | ex14-1_001.jpg | GRAPHIC | 6156
| Complete submission text file | 0001213900-24-076184.txt |  | 2261549

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
24 | XBRL SCHEMA FILE | orka-20240829.xsd | EX-101.SCH | 3257
25 | XBRL DEFINITION FILE | orka-20240829_def.xml | EX-101.DEF | 26188
26 | XBRL LABEL FILE | orka-20240829_lab.xml | EX-101.LAB | 35952
27 | XBRL PRESENTATION FILE | orka-20240829_pre.xml | EX-101.PRE | 24846
38 | EXTRACTED XBRL INSTANCE DOCUMENT | ea0213193-8k_orukathera_htm.xml | XML | 5351

Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 241282218
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)